<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput xmlns:ns2="local" id="73206"><DrugName>bimagrumab</DrugName><DrugNamesKey><Name id="42999318">bimagrumab</Name></DrugNamesKey><DrugSynonyms><Name><Value>anti-activin type IIB monoclonal antibody (cachexia/myositis), Novartis</Value></Name><Name><Value>HuCAL-derived monoclonal antibody (myositis/cachexia), MorphoSys AG</Value></Name><Name><Value>HuCAL-derived monoclonal antibody (myositis/cachexia), Novartis</Value></Name><Name><Value>bimagrumab</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>BYM-338</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="21404">MorphoSys AG</CompanyOriginator><CompaniesPrimary><Company id="23137">Novartis AG</Company></CompaniesPrimary><CompaniesSecondary><Company id="21404">MorphoSys AG</Company></CompaniesSecondary><CrossReferences><SourceEntity id="73206" type="Drug"><TargetEntity id="749046" type="siDrug">Bimagrumab</TargetEntity></SourceEntity><SourceEntity id="21404" type="Company"><TargetEntity id="4295869785" type="organizationId">MorphoSys AG</TargetEntity></SourceEntity><SourceEntity id="23137" type="Company"><TargetEntity id="4295890628" type="organizationId">Novartis AG</TargetEntity></SourceEntity><SourceEntity id="1091" type="ciIndication"><TargetEntity id="10017076" type="MEDDRA"></TargetEntity><TargetEntity id="D050723" type="MeSH"></TargetEntity><TargetEntity id="-1417017400" type="omicsDisease"></TargetEntity><TargetEntity id="1166" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2474" type="ciIndication"><TargetEntity id="M60" type="ICD10"></TargetEntity><TargetEntity id="10028653" type="MEDDRA"></TargetEntity><TargetEntity id="D009220" type="MeSH"></TargetEntity><TargetEntity id="-101206515" type="omicsDisease"></TargetEntity><TargetEntity id="138" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3210" type="ciIndication"><TargetEntity id="10063024" type="MEDDRA"></TargetEntity><TargetEntity id="D055948" type="MeSH"></TargetEntity><TargetEntity id="-531960762" type="omicsDisease"></TargetEntity><TargetEntity id="1319" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3446" type="ciIndication"><TargetEntity id="G72.41" type="ICD10"></TargetEntity><TargetEntity id="10066407" type="MEDDRA"></TargetEntity><TargetEntity id="D018979" type="MeSH"></TargetEntity><TargetEntity id="611" type="ORPHANET"></TargetEntity></SourceEntity><SourceEntity id="425" type="ciIndication"><TargetEntity id="R64" type="ICD10"></TargetEntity><TargetEntity id="10006895" type="MEDDRA"></TargetEntity><TargetEntity id="D002100" type="MeSH"></TargetEntity><TargetEntity id="-1500634021" type="omicsDisease"></TargetEntity><TargetEntity id="1127" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="546" type="ciIndication"><TargetEntity id="10003694" type="MEDDRA"></TargetEntity><TargetEntity id="D001284" type="MeSH"></TargetEntity><TargetEntity id="-1203040124" type="omicsDisease"></TargetEntity><TargetEntity id="3245" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="837" type="ciIndication"><TargetEntity id="E11" type="ICD10"></TargetEntity><TargetEntity id="10067585" type="MEDDRA"></TargetEntity><TargetEntity id="D003924" type="MeSH"></TargetEntity><TargetEntity id="-1888632793" type="omicsDisease"></TargetEntity><TargetEntity id="509" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity><SourceEntity id="4578" type="Action"><TargetEntity id="5495" type="Mechanism">Anti-Activin Receptor Type-2A (ACVR2A; ACTR-IIA)</TargetEntity><TargetEntity id="3786" type="Mechanism">Activin Receptor Type II (ActR-II) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="4574" type="Action"><TargetEntity id="3787" type="Mechanism">Activin Receptor Type IIB (ActR-IIB) Inhibitors</TargetEntity><TargetEntity id="4284" type="Mechanism">Anti-Activin Receptor Type-2B (ACVR2B; ACTR-IIB)</TargetEntity></SourceEntity><SourceEntity id="399" type="Action"><TargetEntity id="884" type="Mechanism">Glucose Lowering Agents</TargetEntity></SourceEntity><SourceEntity id="PTGT-00051" type="ciTarget"><TargetEntity id="301258007923" type="siTarget">Activin receptor type-2A</TargetEntity><TargetEntity id="7023" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-00052" type="ciTarget"><TargetEntity id="723834212933" type="siTarget">Activin receptor type-2B</TargetEntity><TargetEntity id="7024" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C2">Phase 2 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="3">Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="837">Non-insulin dependent diabetes</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1091">Bone injury</Indication><Indication id="2474">Myositis</Indication><Indication id="3210">Sarcopenia</Indication><Indication id="3446">Inclusion body myositis</Indication><Indication id="425">Cachexia</Indication><Indication id="546">Atrophy</Indication></IndicationsSecondary><ActionsPrimary><Action id="4578">Activin type-II receptor antagonist</Action><Action id="4574">Activin type-IIB receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="399">Hypoglycemic agent</Action><Action id="1408">Muscle system agent</Action><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="168">Monoclonal antibody human</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="740">Infusion</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="85">Protein recombinant</Technology></Technologies><LastModificationDate>2019-06-06T13:51:39.000Z</LastModificationDate><ChangeDateLast>2019-06-07T00:00:00.000Z</ChangeDateLast><AddedDate>2011-08-26T15:42:09.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="23137" linkType="Company"&gt;Novartis&lt;/ulink&gt;, under license from &lt;ulink linkID="21404" linkType="Company"&gt;Morphosys AG&lt;/ulink&gt;, is developing bimagrumab (BYM-338), a recombinant human HuCAL-based    mAb against the activin type IIB receptor (ACVR2B), for the potential treatment of type 2 diabetes  [&lt;ulink linkID="1023481" linkType="Reference"&gt;1023481&lt;/ulink&gt;], [&lt;ulink linkID="1567444" linkType="Reference"&gt;1567444&lt;/ulink&gt;], [&lt;ulink linkID="1889097" linkType="Reference"&gt;1889097&lt;/ulink&gt;], [&lt;ulink linkID="2119074" linkType="Reference"&gt;2119074&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2017, a phase II trial for overweight and obese patients with type 2 diabetes was initiated [&lt;ulink linkID="1889097" linkType="Reference"&gt;1889097&lt;/ulink&gt;]; in March 2018, the trial was ongoing [&lt;ulink linkID="2019644" linkType="Reference"&gt;2019644&lt;/ulink&gt;]; in February 2019, phase II development in this setting was ongoing [&lt;ulink linkID="2119074" linkType="Reference"&gt;2119074&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The drug was previously being developed for other indications. In August 2011, a phase II trial for cancer-related cachexia was initiated; in April 2014, the trial was completed [&lt;ulink linkID="1234548" linkType="Reference"&gt;1234548&lt;/ulink&gt;]. In September 2012, a phase II trial began in chronic obstructive pulmonary disease (COPD) patients with cachexia. In December 2014, the trial was completed [&lt;ulink linkID="1779955" linkType="Reference"&gt;1779955&lt;/ulink&gt;]; however, in January 2016,  cachexia in patients with cancer or COPD  was no longer listed as being under investigation [&lt;ulink linkID="1739632" linkType="Reference"&gt;1739632&lt;/ulink&gt;]. In October 2013, a phase II/III trial  for sporadic inclusion body myositis began [&lt;ulink linkID="1482982" linkType="Reference"&gt;1482982&lt;/ulink&gt;], [&lt;ulink linkID="1483408" linkType="Reference"&gt;1483408&lt;/ulink&gt;]; at that time, the company expected to file for this indication in 2016 [&lt;ulink linkID="1490461" linkType="Reference"&gt;1490461&lt;/ulink&gt;]; in January 2016, this was still the case [&lt;ulink linkID="1739632" linkType="Reference"&gt;1739632&lt;/ulink&gt;]; however, in April 2016, negative data from the RESILIENT trial were reported [&lt;ulink linkID="1754147" linkType="Reference"&gt;1754147&lt;/ulink&gt;], [&lt;ulink linkID="1754306" linkType="Reference"&gt;1754306&lt;/ulink&gt;]; in January 2017, Novartis confirmed that sporadic inclusion body myositis development had been discontinued [&lt;ulink linkID="1896505" linkType="Reference"&gt;1896505&lt;/ulink&gt;]. In October 2013, Novartis listed the drug as being in phase II development for hip fracture [&lt;ulink linkID="1490461" linkType="Reference"&gt;1490461&lt;/ulink&gt;]. In April 2014, a phase II trial in patients with atrophy after hip fracture surgery began [&lt;ulink linkID="1603364" linkType="Reference"&gt;1603364&lt;/ulink&gt;]; in March 2018, phase II development in this setting was ongoing [&lt;ulink linkID="2019644" linkType="Reference"&gt;2019644&lt;/ulink&gt;]. In December 2014, a phase II  study for sarcopenia was initiated [&lt;ulink linkID="1626466" linkType="Reference"&gt;1626466&lt;/ulink&gt;]; in March 2018, phase II development in this setting was ongoing [&lt;ulink linkID="2019644" linkType="Reference"&gt;2019644&lt;/ulink&gt;]. In January 2018, the drug was still in phase II for hip fracture recovery and sarcopenia and the company expected to submit filings for both indications  in 2022 or later  [&lt;ulink linkID="2004756" linkType="Reference"&gt;2004756&lt;/ulink&gt;]; however, in January 2019, Novartis listed development of the drug in both hip fracture recovery and sarcopenia as discontinued [&lt;ulink linkID="2116311" linkType="Reference"&gt;2116311&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In January 2018, filings for hip fracture recovery and sarcopenia  were expected in 2022 or later  [&lt;ulink linkID="2004756" linkType="Reference"&gt;2004756&lt;/ulink&gt;]; however, in January 2019, Novartis listed development of the drug in these settings as discontinued [&lt;ulink linkID="2116311" linkType="Reference"&gt;2116311&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2012, the FDA granted the drug Orphan designation for the treatment of inclusion body myositis [&lt;ulink linkID="1308537" linkType="Reference"&gt;1308537&lt;/ulink&gt;];  in August 2013, the FDA also granted Breakthrough Therapy designation for sporadic inclusion body myositis [&lt;ulink linkID="1467364" linkType="Reference"&gt;1467364&lt;/ulink&gt;]. In October 2013, the company expected to file for this indication in 2016 [&lt;ulink linkID="1490461" linkType="Reference"&gt;1490461&lt;/ulink&gt;]; in January 2016, this was still the case [&lt;ulink linkID="1739632" linkType="Reference"&gt;1739632&lt;/ulink&gt;]; however, in January 2017, Novartis confirmed that sporadic inclusion body myositis development had been discontinued [&lt;ulink linkID="1896505" linkType="Reference"&gt;1896505&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In January 2018, filings for hip fracture recovery and sarcopenia  were expected in 2022 or later  [&lt;ulink linkID="2004756" linkType="Reference"&gt;2004756&lt;/ulink&gt;]; however, in January 2019, Novartis listed development of the drug in these settings as discontinued [&lt;ulink linkID="2116311" linkType="Reference"&gt;2116311&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2012, the COMP of the EMA recommended Orphan status for the treatment of inclusion body myositis [&lt;ulink linkID="1309175" linkType="Reference"&gt;1309175&lt;/ulink&gt;]; in August 2012, Orphan status was granted [&lt;ulink linkID="1323703" linkType="Reference"&gt;1323703&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;In January 2018,  filings for hip fracture recovery and sarcopenia  were expected in 2022 or later  [&lt;ulink linkID="2004756" linkType="Reference"&gt;2004756&lt;/ulink&gt;]; however, in January 2019, Novartis listed development of the drug in these settings as discontinued [&lt;ulink linkID="2116311" linkType="Reference"&gt;2116311&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2013, the Pharmaceutical Affairs and Food Sanitation Council's First Committee on Drugs was to discuss Orphan Drug designation for inclusion body myositis at a meeting in August 2013 [&lt;ulink linkID="1465602" linkType="Reference"&gt;1465602&lt;/ulink&gt;]; by September 2013, the drug had been awarded Orphan designation for inclusion body myositis [&lt;ulink linkID="1477433" linkType="Reference"&gt;1477433&lt;/ulink&gt;]; in May 2019, the Orphan designation for inclusion body myositis was rescinded [&lt;ulink linkID="2159817" linkType="Reference"&gt;2159817&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Inclusion body myositis&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In April 2018, clinical data from RESILIENT extension study (&lt;ulink linkID="243029" linkType="Protocol"&gt;NCT02573467&lt;/ulink&gt;) which evaluated the safety and efficacy of bimagrumab, in patients with inclusion body myositis were presented at the 70th AAN Annual Meeting in Los Angeles, CA. Patients (n = 211) were randomized to receive bimagrumab (10, 3, 1 mg/kg) or placebo q4w. In bimagrumab (10, 3, 1 mg/kg) or placebo groups, the mean change in 6 min walking Test showed highly variable but progressive decline was observed at week 104. From week 52 to 78, the mean change of Sporadic Inclusion Body Myositis Functional Assessment total score was increased from baseline in bimagrumab (10 mg/kg) and placebo (-1.34 and 5.16 versus -0.27and 7.41, respectively) and at week 104, responses were converging with a mean change of 3.54 and 7.39, respectively. Diarrhea (14.7%), muscle spasm (9.6%) and rash (5.1%) were the most common reported adverse events in bimagrumab group [&lt;ulink linkID="2026103" linkType="Reference"&gt;2026103&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2015, clinical data were presented from a randomized phase II/III study (&lt;ulink linkID="211821" linkType="Protocol"&gt;NCT02250443&lt;/ulink&gt;) in 14 patients with sporadic inclusion body myositis at the 16th EULAR Annual European Congress in Rome, Italy.​ Patients were randomized to receive single dose of bimagrumab (30 mg/kg, iv) or placebo. A reduction in % fat fraction (−7% versus baseline) was noted at week 8 in four patients, while sc and im adipose tissue (IMAT) volumes were slightly reduced. The increase in the individual muscle volumes (IMVs) was greater in the posterior (+8%) when compared with the anterior thigh compartment (+4%). At week-16, additional decrease in IMAT in all muscles (-7% versus baseline) correlated well with the change from baseline in IMV at week-8 [&lt;ulink linkID="1668737" linkType="Reference"&gt;1668737&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2013, a phase II/III randomized, double-blind, placebo-controlled, dose-finding efficacy, safety and  tolerability 52-week study (&lt;ulink linkID="151669" linkType="Protocol"&gt;NCT01925209&lt;/ulink&gt;; CBYM338B2203; RESILIENT) of iv BYM-338 was expected to begin in sporadic inclusion body myositis patients (expected n = 240) in September 2013; at that time, the study was expected to complete in November 2015 [&lt;ulink linkID="1482982" linkType="Reference"&gt;1482982&lt;/ulink&gt;]. The trial began in October 2013 and was expected to run at sites in Australia, Europe and Japan [&lt;ulink linkID="1483408" linkType="Reference"&gt;1483408&lt;/ulink&gt;]. In April 2016, data from the study were reported, which showed that bimagrumab did not meet its primary endpoint. At that time, the company was reviewing the data and stated that ongoing clinical trials were not being discontinued [&lt;ulink linkID="1754147" linkType="Reference"&gt;1754147&lt;/ulink&gt;]. In November 2016, further clinical data were presented at the 80th ACR Annual Meeting in Washington DC. Bimagrumab was well-tolerated, increased LBM and showed a potential benefit in PRO, but did not reach the primary endpoint of improving 6MWD or showed an improvement in muscle strength [&lt;ulink linkID="1884076" linkType="Reference"&gt;1884076&lt;/ulink&gt;]. In April 2017, further efficacy and safety data were presented at the 69th AAN Annual Meeting in Boston, MA. At week 52, in patients receiving 10, 3, 1 mg/kg bimagrumab and placebo, percentage of participants who improved or had no clinically significant deterioration in the Sporadic Inclusion Body Myositis Functional Assessment scores were 55, 46, 40 and 30, respectively. During the study, one death each occurred in bimagrumab 10 and 1 mg/kg groups due to subendocardial myocardial infarction and lung adenocarcinoma, and both were considered unrelated to the study drug [&lt;ulink linkID="1920089" linkType="Reference"&gt;1920089&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In August 2011, a randomized, double-blind, placebo-controlled, phase II study (&lt;ulink linkID="80311" linkType="Protocol"&gt;NCT01423110&lt;/ulink&gt;; CBYM338X2205) was initiated in patients with sporadic inclusion body myositis (expected n = 12) in the US, to assess the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of BYM-338. The study was completed in May  2012 [&lt;ulink linkID="1217931" linkType="Reference"&gt;1217931&lt;/ulink&gt;]. By August 2013, results from the phase II study  submitted to the FDA had shown bimagrumab to substantially benefit patients with sporadic inclusion body myositis compared with placebo;  at that time, these results were scheduled to be presented at the American Neurological Association meeting in New Orleans, LA, in October 2013 [&lt;ulink linkID="1467364" linkType="Reference"&gt;1467364&lt;/ulink&gt;]. In January 2015, further data demonstrating that bimagrumab resulted in a significant improvement in both  muscle mass (approximately 5% more than placebo) and function were presented at the 33rd Annual JPMorgan Healthcare Conference in San Francisco, CA [&lt;ulink linkID="1626759" linkType="Reference"&gt;1626759&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2013, Novartis filed a clinical trial application of bimagrumab in China, presumed to be for inclusion body myositis [&lt;ulink linkID="1505488" linkType="Reference"&gt;1505488&lt;/ulink&gt;], [&lt;ulink linkID="1511220" linkType="Reference"&gt;1511220&lt;/ulink&gt;]. In January 2016, review of the application was concluded though the outcome was not published yet [&lt;ulink linkID="1727232" linkType="Reference"&gt;1727232&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Sarcopenia&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In August 2016, a 28-week, randomized, double-blind, placebo-controlled, parallel group, withdrawal extension  phase II study (&lt;ulink linkID="231835" linkType="Protocol"&gt;NCT02468674&lt;/ulink&gt;; CBYM338E2202E1; CORE) to evaluate the durability of effect on skeletal muscle strength and function upon withdrawal of the drug  in older adults with sarcopenia, was initiated in the US, Japan, Taiwan, Spain and Denmark. The study was to complete in  February 2018 [&lt;ulink linkID="1794487" linkType="Reference"&gt;1794487&lt;/ulink&gt;]. In March 2018, the trial was ongoing [&lt;ulink linkID="2019644" linkType="Reference"&gt;2019644&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2014, a randomized, double-blind, placebo-controlled, multi-center, parallel group, dose range finding phase II  study (&lt;ulink linkID="219595" linkType="Protocol"&gt;NCT02333331&lt;/ulink&gt;; CBYM338E2202; InvestiGAIT) was initiated in the US, in patients (expected n = 280) with sarcopenia, to  assess the effect of monthly doses of bimagrumab on skeletal muscle strength and function  [&lt;ulink linkID="1626466" linkType="Reference"&gt;1626466&lt;/ulink&gt;], [&lt;ulink linkID="1929729" linkType="Reference"&gt;1929729&lt;/ulink&gt;]. The trial was yet to initiate in Japan, Spain and Taiwan. At that time, the trial was expected to complete in August 2016. By April 2015, the trial was recruiting in Japan and Taiwan. In  December 2015, the trial was ongoing in Belgium, Denmark, France, Germany and  Switzerland [&lt;ulink linkID="1626466" linkType="Reference"&gt;1626466&lt;/ulink&gt;]. In February 2017, the protocol was approved in Korea [&lt;ulink linkID="1923602" linkType="Reference"&gt;1923602&lt;/ulink&gt;]. In March 2018, the trial was ongoing [&lt;ulink linkID="2019644" linkType="Reference"&gt;2019644&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2012, a randomized, double-blind, placebo-controlled, phase II study (&lt;ulink linkID="87572" linkType="Protocol"&gt;NCT01601600&lt;/ulink&gt;; CBYM338X2201) was initiated in patients with sarcopenia (expected n = 40) in the US, to assess the safety and efficacy of BYM-388. At that time, the study was scheduled to complete in December 2012 [&lt;ulink linkID="1293086" linkType="Reference"&gt;1293086&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Cachexia&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In September 2012, a randomized, double-blind, placebo-controlled, multi-centre, phase II trial (&lt;ulink linkID="90818" linkType="Protocol"&gt;NCT01669174&lt;/ulink&gt;; CBYM338X2204; 2011-000461-12) began in COPD patients (n = 67) with cachexia. The primary endpoint was the percentage change from baseline of thigh muscle volume by MRI scan at week 4, 8, 16, and 24. In December 2014, the trial was completed [&lt;ulink linkID="1779955" linkType="Reference"&gt;1779955&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By June 2011, a randomized, double-blind, placebo-controlled, phase II study (VAR0067) was planned in patients with stage IV NSCLC or stage III/IV pancreas adenocarcinoma with unintentional weight loss, to assess the safety and efficacy of BYM-338. The study was expected to begin later that year and complete in 2012 [&lt;ulink linkID="1217934" linkType="Reference"&gt;1217934&lt;/ulink&gt;], [&lt;ulink linkID="1217935" linkType="Reference"&gt;1217935&lt;/ulink&gt;]. In August 2011, a  multicenter, phase II trial (&lt;ulink linkID="80674" linkType="Protocol"&gt;NCT01433263&lt;/ulink&gt;;CBYM338X2202) began in patients (expected n=50) in the US, and was expected to be completed in September 2012. At that time, patient recruitment had not been initiated in the UK and Switzerland. In April 2014, the trial was completed [&lt;ulink linkID="1234548" linkType="Reference"&gt;1234548&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Hip fracture&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In September 2014, a 56-week, randomized, multicenter, double-blind, placebo-controlled phase II trial (&lt;ulink linkID="193142" linkType="Protocol"&gt;NCT02152761&lt;/ulink&gt;; CBYM338D2201) was initiated in the US, Belgium and Japan, in patients (n = 210) with atrophy after hip fracture surgery. The trial was expected to complete in December 2016.	In March 2016, the trial was ongoing in Czech Republic, Germany, Hungary, Mexico, Romania, Russian Federation, Spain, Switzerland, Taiwan and the UK [&lt;ulink linkID="1603364" linkType="Reference"&gt;1603364&lt;/ulink&gt;]. In March 2018, the trial was ongoing [&lt;ulink linkID="2019644" linkType="Reference"&gt;2019644&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Muscle wasting&lt;/subtitle&gt;In May 2016,  data from a  double-blind, randomized, placebo-controlled, phase IIa study (EudraCT: &lt;ulink linkID="90818" linkType="Protocol"&gt;2011-000461-12-NL&lt;/ulink&gt;) which evaluated the safety and efficacy of bimagrumab in patients with COPD-associated skeletal muscle wasting were presented at the 2016 ATS International Conference in San Francisco, CA. Patients (n = 67) were randomized to receive either bimagrumab (30 mg/kg, n = 33) or placebo (n = 34) iv, at day 0 and 57 in a double-blind fashion. At weeks 4, 8, and 24, the changes in thigh muscle volume (primary endpoint) were +5.87, +7.01 and +5.04% in patients treated with bimagrumab and 0.02, -0.65 and -1.29% in placebo-treated patients, respectively [&lt;ulink linkID="1765816" linkType="Reference"&gt;1765816&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Type 2 diabetes&lt;/subtitle&gt;In February 2017, a randomized, double-blind, parallel-group, placebo-controlled phase II trial (&lt;ulink linkID="283621" linkType="Protocol"&gt;NCT03005288&lt;/ulink&gt;; CBYM338X2211) to evaluate the safety and efficacy of bimagrumab in obese patients (expected n = 60) with type 2 diabetes began in the US. The primary endpoint would be the change in fat body mass as measured by DXA [&lt;ulink linkID="1889097" linkType="Reference"&gt;1889097&lt;/ulink&gt;], [&lt;ulink linkID="1892091" linkType="Reference"&gt;1892091&lt;/ulink&gt;]. By May 2017, the inclusion criteria for the trial had been updated to include both overweight and obese patients (expected n = 60).  At that time, the trial was expected to complete in January 2019 [&lt;ulink linkID="1889097" linkType="Reference"&gt;1889097&lt;/ulink&gt;]. In March 2018, the trial was ongoing [&lt;ulink linkID="2019644" linkType="Reference"&gt;2019644&lt;/ulink&gt;]; in October 2018, this was still the case [&lt;ulink linkID="1889097" linkType="Reference"&gt;1889097&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other studies&lt;/subtitle&gt;In June 2017, clinical data were presented at 77th ADA Scientific Sessions in San Diego, CA. Healthy subjects (n = 16, 18 to 65 years) were randomized to receive a single dose of bimabrumab 30 mg/kg, iv or placebo. In non-diabetic, insulin resistant subjects, single dose of bimagrumab showed significant improvement in glycohemoglobin A1C (by 0.2%). A linear and significant relationship was observed between reduction of fat body mass and increase in insulin sensitivity (pooled groups), whereas, no relationship reported between changes in lean body mass and insulin sensitivity [&lt;ulink linkID="1936371" linkType="Reference"&gt;1936371&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2014, a randomized, double-blinded, placebo-controlled, interventional, parallel-assigned phase II study (&lt;ulink linkID="136983" linkType="Protocol"&gt;NCT01868685&lt;/ulink&gt;; CBYM338X2207) was initiated to investigate the effect of BYM-338 on muscle in patients requiring prolonged mechanical ventilation. At that time, the study was to complete in January 2015. In June 2014, the study was withdrawn [&lt;ulink linkID="1911507" linkType="Reference"&gt;1911507&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2016, clinical data from a randomized, double-blind, placebo-controlled study which evaluated the safety and efficacy of bimagrumab in 44 healthy older adults  were presented at the Second EAN Congress in Copenhagen, Denmark. At week 8, change in mean fasting total testosterone levels from baseline was -85.31 and -1.87 ng/dl (primary endpoint); follicle-stimulating hormone levels was -1.13 and -42.16 IU/l; luteinizing hormone (LH) was -1.51 and 2.50 IU/l; estradiol was 1.88 and 26.19 picoM/l; dehydroepiandrosterone sulphase  was -4.60 and -3.61 microg/dl; cortisol (at 60 min after adrenocorticotropic hormone stimulation) was 79.92 and 38.71 nmol/l in men and women post treatment, respectively. Adverse events  reported were more among women than men. No serious adverse events were reported [&lt;ulink linkID="1789683" linkType="Reference"&gt;1789683&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2016, clinical data from a  randomized, double-blind, placebo-controlled, phase I study which evaluated the safety and efficacy of bimagrumab in 68 healthy older adults were presented at  the Second EAN Congress in Copenhagen, Denmark. No significant change in left ventricular ejection fraction and left ventricular mass index was observed with bimagrumab compared with placebo, at 6 months. Total lean body mass was 1.06 versus 1.00 with bimagrumab versus placebo treatments, respectively. There was no difference in wall thicknesses, ventricular volumes, heart rate, Fridericia-corrected QT interval values or frequency of ventricular arrhythmias between bimagrumab and placebo treatment groups. Most frequently reported adverse event was muscle spasm [&lt;ulink linkID="1787782" linkType="Reference"&gt;1787782&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In  May 2019, preclinical data were presented at 2019 AUA Annual Meeting in Chicago, IL. In rats, leak point pressure was significantly increased with bimagrumab via activin type II receptors blockade which demonstrated strongest effect on muscle growth [&lt;ulink linkID="2150642" linkType="Reference"&gt;2150642&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2013, preclinical data were published. Data demonstrated that, BYM-338 boosted muscle mass 25 to 50% and increased strength in animal models. Differentiation of primary human skeletal myoblasts was enhanced and inhibition of differentiation induced by myostatin or activin A was counteracted by BYM-338. BYM-338 also prevented myostatin or Activin A induced atrophy through inhibition of Smad2/3 phosphorylation. Enhanced muscle hypertrophy was induced in myostatin-mutant mice by a mouse version of the antibody. BYM-338 also protected muscles from glucocorticoid-induced atrophy and weakness, through prevention of muscle and tetanic force losses [&lt;ulink linkID="1510563" linkType="Reference"&gt;1510563&lt;/ulink&gt;], [&lt;ulink linkID="1510523" linkType="Reference"&gt;1510523&lt;/ulink&gt;]&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In July 2012, the pediatric committee adopted a positive opinion to waive the requirement for data from clinical trials in children [&lt;ulink linkID="1308399" linkType="Reference"&gt;1308399&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-02-20T00:00:00.000Z</StatusDate><Source id="1889097" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1091">Bone injury</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-01-30T00:00:00.000Z</StatusDate><Source id="2116311" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="546">Atrophy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-01-30T00:00:00.000Z</StatusDate><Source id="2116311" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="546">Atrophy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-01-30T00:00:00.000Z</StatusDate><Source id="2116311" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3446">Inclusion body myositis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-01-25T00:00:00.000Z</StatusDate><Source id="1896505" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3210">Sarcopenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-01-30T00:00:00.000Z</StatusDate><Source id="2116311" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3210">Sarcopenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-01-30T00:00:00.000Z</StatusDate><Source id="2116311" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3210">Sarcopenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-01-30T00:00:00.000Z</StatusDate><Source id="2116311" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1091">Bone injury</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-01-30T00:00:00.000Z</StatusDate><Source id="2116311" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3210">Sarcopenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-01-30T00:00:00.000Z</StatusDate><Source id="2116311" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3446">Inclusion body myositis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-01-25T00:00:00.000Z</StatusDate><Source id="2116311" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3446">Inclusion body myositis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-01-25T00:00:00.000Z</StatusDate><Source id="1896505" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1091">Bone injury</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-01-30T00:00:00.000Z</StatusDate><Source id="2116311" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="546">Atrophy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-01-30T00:00:00.000Z</StatusDate><Source id="2116311" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="546">Atrophy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-01-30T00:00:00.000Z</StatusDate><Source id="2116311" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1091">Bone injury</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-01-30T00:00:00.000Z</StatusDate><Source id="2116311" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3210">Sarcopenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-01-30T00:00:00.000Z</StatusDate><Source id="2116311" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3446">Inclusion body myositis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-01-25T00:00:00.000Z</StatusDate><Source id="1896505" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1091">Bone injury</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-01-30T00:00:00.000Z</StatusDate><Source id="2116311" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="546">Atrophy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-01-30T00:00:00.000Z</StatusDate><Source id="2116311" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3446">Inclusion body myositis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-01-25T00:00:00.000Z</StatusDate><Source id="1896505" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="425">Cachexia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-01-27T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="425">Cachexia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-01-27T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="425">Cachexia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-01-27T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21404">MorphoSys AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2474">Myositis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-07-06T00:00:00.000Z</StatusDate><Source id="1023481" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21404">MorphoSys AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="425">Cachexia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-07-06T00:00:00.000Z</StatusDate><Source id="1023481" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3446">Inclusion body myositis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-07-23T00:00:00.000Z</StatusDate><Source id="1465602" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3210">Sarcopenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-01-06T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3210">Sarcopenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-01-06T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="ES">Spain</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3210">Sarcopenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-01-06T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="425">Cachexia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-08-24T00:00:00.000Z</StatusDate><Source id="1234548" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="425">Cachexia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-06-16T00:00:00.000Z</StatusDate><Source id="1217935" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="425">Cachexia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-08-24T00:00:00.000Z</StatusDate><Source id="1234548" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3446">Inclusion body myositis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-08-24T00:00:00.000Z</StatusDate><Source id="1217931" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3446">Inclusion body myositis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-10-02T00:00:00.000Z</StatusDate><Source id="1483408" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3446">Inclusion body myositis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-10-02T00:00:00.000Z</StatusDate><Source id="1483408" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3446">Inclusion body myositis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-10-02T00:00:00.000Z</StatusDate><Source id="1483408" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3446">Inclusion body myositis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-12-12T00:00:00.000Z</StatusDate><Source id="1511220" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1091">Bone injury</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-10-22T00:00:00.000Z</StatusDate><Source id="1490461" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3210">Sarcopenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-02-23T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1091">Bone injury</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-03-29T00:00:00.000Z</StatusDate><Source id="1603364" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1091">Bone injury</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-03-29T00:00:00.000Z</StatusDate><Source id="1603364" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1091">Bone injury</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-09-30T00:00:00.000Z</StatusDate><Source id="1603364" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1091">Bone injury</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-09-30T00:00:00.000Z</StatusDate><Source id="1603364" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1091">Bone injury</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-09-30T00:00:00.000Z</StatusDate><Source id="1603364" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3210">Sarcopenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-11-21T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="546">Atrophy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-09-30T00:00:00.000Z</StatusDate><Source id="1603364" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="546">Atrophy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-09-30T00:00:00.000Z</StatusDate><Source id="1603364" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="546">Atrophy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-09-30T00:00:00.000Z</StatusDate><Source id="1603364" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="546">Atrophy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-03-29T00:00:00.000Z</StatusDate><Source id="1603364" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="546">Atrophy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-03-29T00:00:00.000Z</StatusDate><Source id="1603364" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3210">Sarcopenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-04-27T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3210">Sarcopenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-12-09T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3210">Sarcopenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-04-27T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3210">Sarcopenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-05-17T00:00:00.000Z</StatusDate><Source id="1293086" type="TRIALREG"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="3">Breakthrough Therapy</RegulatoryDesignation><OwnerCompany id="23137">Novartis AG</OwnerCompany><Country id="US">US</Country><Indication id="3446">Inclusion body myositis</Indication><AwardedIndication>Treatment of sporadic inclusion body myositis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-08-20T00:00:00.000Z</MileStoneDate><Source id="1467364" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23137">Novartis AG</OwnerCompany><Country id="JP">Japan</Country><Indication id="3446">Inclusion body myositis</Indication><AwardedIndication>Treatment of inclusion body myositis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="9">Withdrawn</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-05-30T00:00:00.000Z</MileStoneDate><Source id="2159817" type="CORPORATE"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23137">Novartis AG</OwnerCompany><Country id="JP">Japan</Country><Indication id="3446">Inclusion body myositis</Indication><AwardedIndication>Inclusion body myositis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-09-03T00:00:00.000Z</MileStoneDate><Source id="1477433" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23137">Novartis AG</OwnerCompany><Country id="EU">EU</Country><Indication id="3446">Inclusion body myositis</Indication><AwardedIndication>Treatment of inclusion-body myositis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-08-09T00:00:00.000Z</MileStoneDate><Source id="1323703" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23137">Novartis AG</OwnerCompany><Country id="EU">EU</Country><Indication id="3446">Inclusion body myositis</Indication><AwardedIndication>Treatment of inclusion-body myositis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-07-11T00:00:00.000Z</MileStoneDate><Source id="1309175" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23137">Novartis AG</OwnerCompany><Country id="US">US</Country><Indication id="3446">Inclusion body myositis</Indication><AwardedIndication>Treatment of inclusion body myositis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-06-18T00:00:00.000Z</MileStoneDate><Source id="1308537" type="CORPORATE"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00051"><Name>Activin type-II receptor</Name><SwissprotNumbers><Swissprot>P27037</Swissprot><Swissprot>P27038</Swissprot><Swissprot>P27039</Swissprot><Swissprot>P38444</Swissprot><Swissprot>Q28043</Swissprot><Swissprot>Q28560</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00052"><Name>Activin type-IIB receptor</Name><SwissprotNumbers><Swissprot>P27040</Swissprot><Swissprot>P27041</Swissprot><Swissprot>P38445</Swissprot><Swissprot>Q13705</Swissprot><Swissprot>Q95126</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2150642" linkType="reference" linkID="2150642"&gt;2150642&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="21404">MorphoSys AG</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="23137">Novartis AG</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="110241" title="Novartis to codevelop antibodies using MorphoSys' technologies                        "></Deal></Deals><PatentFamilies><PatentFamily id="2373530" number="WO-2010125003" title="Compositions and methods for increasing muscle growth"></PatentFamily><PatentFamily id="2447209" number="WO-2013006437" title="Method for treating metabolic disorders"></PatentFamily><PatentFamily id="2977698" number="WO-2015111008" title="Biomarkers predictive of muscle atrophy, method and use"></PatentFamily><PatentFamily id="3058461" number="WO-2015162590" title="Methods of improving or accelerating physical recovery after surgery for hip fracture"></PatentFamily><PatentFamily id="3203975" number="WO-2016092439" title="Myostatin or activin antagonists for the treatment of sarcopenia"></PatentFamily><PatentFamily id="3630767" number="WO-2017081624" title="Uses of myostatin antagonists, combinations containing them and uses thereof"></PatentFamily><PatentFamily id="4104887" number="WO-2018116201" title="Myostatin, activin or activin receptor antagonists for use in treating obesity and related conditions"></PatentFamily><PatentFamily id="4190699" number="WO-2018162931" title="Method relating to myostatin pathway inhibition"></PatentFamily><PatentFamily id="4205326" number="WO-2018175460" title="Methods for preventing and treating heart disease"></PatentFamily><PatentFamily id="4328631" number="WO-2019003104" title="Methods for preventing and treating urinary incontinence"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>8</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Massachusetts General Hospital Cancer Center" id="1127918"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johnson &amp; Johnson" id="17332"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of London" id="20607"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tufts University" id="20689"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"></CompanyLink><CountAsOwner>9</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>9</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Harvard Medical School" id="24839"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput>